France set to become even tougher for medtech as elections loom: the details
This article was originally published in Clinica
Executive Summary
2012 is set to be a year full of important decisions impacting the French landscape, brought on by the climate of uncertainty resulting from recent healthcare product scandals. Alexandre Regniault, partner at the Paris office of law firm Simmons & Simmons, reflects on the current climate and the impact of the latest French regulatory measures
You may also be interested in...
No easy choice: managing infectious waste from self-treating patients in France
What are the rules in France regarding infectious medical waste that is generated by self-treating patients? Alexandre Regniault, partner at the Paris office of law firm Simmons & Simmons, explains the pros and cons of the two options open to medical device companies
The revision of the EU medical device directives and variations in national laws
How successful have the EU member states been in implementing the revision of the medical device directives into national law? And has this been done in a harmonised way? Alexandre Regniault and colleagues report on variations that have resulted from deviations from the original directives and their impact.
The revision of the EU medical device directives and variations in national laws
How successful have the EU member states been in implementing the revision of the medical device directives into national law? And has this been done in a harmonised way? Alexandre Regniault and colleagues report on variations that have resulted from deviations from the original directives and their impact.